Vejtorp M, Christensen M S, Vejtorp L, Larsen J F
Acta Obstet Gynecol Scand. 1986;65(5):391-5. doi: 10.3109/00016348609157370.
Thirty perimenopausal women were randomized to sequential therapy with either estradiol-valerate and norgestrel (Cyclo-Progynon), or estradiol and medroxy-progesterone acetate (EM 627). Blood samples were drawn before treatment and in the third treatment cycle during estrogen and progestogen phases respectively. The clinical effects of the two treatments were without significant difference. Ovulation was not suppressed by the treatments, which induced similar increases in serum estradiol and estrone concentrations. The medium serum high density lipoprotein-(HDL)-cholesterol concentration expressed as a percentage of the pretreatment level decreased in the postmenopausal women treated with Cyclo-Progynon to 90% compared with 104% (p less than 0.01) in the EM 627 group. However, the concentrations expressed in mmol/l did not differ significantly, probably owing to non-significant differences in the pretreatment levels. Low density lipoprotein-(LDL)-cholesterol concentrations decreased by approximately 10% in the postmenopausal women during both treatments. Cyclic addition of medroxy-progesterone acetate to estrogen replacement therapy does not adversely affect the serum lipoprotein pattern, and may be preferable to norgestrel.
30名围绝经期妇女被随机分为两组，分别接受戊酸雌二醇和炔诺孕酮序贯治疗（Cyclo - Progynon），或雌二醇和醋酸甲羟孕酮序贯治疗（EM 627）。在治疗前以及第三个治疗周期的雌激素期和孕激素期分别采集血样。两种治疗的临床效果无显著差异。这些治疗未抑制排卵，且两种治疗均使血清雌二醇和雌酮浓度出现相似程度的升高。以绝经前水平的百分比表示，接受Cyclo - Progynon治疗的绝经后妇女血清高密度脂蛋白（HDL） - 胆固醇浓度中位数降至90%，而EM 627组为104%（p < 0.01）。然而，以mmol/l表示的浓度差异无统计学意义，可能是由于治疗前水平差异无统计学意义。在两种治疗过程中，绝经后妇女的低密度脂蛋白（LDL） - 胆固醇浓度均下降了约10%。在雌激素替代治疗中周期性添加醋酸甲羟孕酮对血清脂蛋白模式无不利影响，可能比炔诺孕酮更可取。
